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Objectives: The prevalence of both chronic kidney disease (CKD) and upper tract urothelial carcinoma
(UTUC) in Taiwan is unusually high, and we aimed to investigate the impact of preoperative renal
function on UTUC after radical nephroureterectomy.
Materials and methods: Between 2000 and 2013, 248 UTUC patients were enrolled in this retrospective
study after excluding patients who had concomitant muscle-invasive bladder cancer, whose tumor
metastasized at initial presentation, and who received perioperative chemotherapy or radiotherapy. The
signiﬁcance of CKD on overall survival (OS), cancer-speciﬁc survival (CSS), and bladder recurrence-free
survival (BRFS) was evaluated by Cox proportional hazard model.
Results: The median follow-up time was 45.41 months. Overall 5-year OS, CSS, and BRFS rates were
78.27%, 87.81%, and 70.42%, respectively. Aging, late-stage CKD, and nonorgan-conﬁned primary tumor
stage were independent predictors for OS after adjustment. Nonorgan-conﬁned primary tumor stage and
lymph node involvement were two independent predictors for CSS after adjustment. Concomitant
bladder tumor was the only signiﬁcant predictor for BRFS after adjustment.
Conclusion: Patients with late-stage CKD had a higher risk of having poor OS. Patients with concomitant
bladder tumor had a greater risk of having bladder cancer recurrence despite primary tumor stage.
Concomitant bladder tumor, however, had no effect on OS and CSS in this study.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Upper tract urothelial carcinoma (UTUC) is an uncommon dis-
ease, and the incidence rate of all UCs in the West is around 5%.1
However, the incidence of UTUC is extraordinarily high in Taiwan,
accounting for about 30% of all UCs.2 Although nephron-sparing
surgery, including partial nephrectomy, segmental ureterectomy,
and endoscopic management, is feasible in selected UTUC patients,
radical nephroureterectomy (RNU) remains the gold standard for
high-grade, invasive UTUC.aohsiung Medical University
y 807, Taiwan.
ciation. Published by Elsevier TaiwChronic kidney disease (CKD) is another popular disease in
Taiwan. According to the 2013 annual report of the United States
Renal Data System, the prevalence of end-stage renal disease in
Taiwan is the highest in the world, and the high dialysis rate leads
to a substantial increase in medical expenses. In addition, the CKD
population have a worse all-cause mortality, increased cardiovas-
cular events, and more frequent hospitalization.3,4 It has been
demonstrated that evaluation of the serum creatinine level alone is
not an ideal tool to estimate renal function.5 Coresh et al6 showed
that around 5% of patients with stage III or greater CKD have normal
serum creatinine levels. Instead, estimated glomerular ﬁltration
rate (eGFR) was clinically applied to represent patients' renal
function.
UTUC is a major cancer in patients with CKD/end-stage renal
disease in Taiwan, but the investigation of the associationan LLC. Open access under CC BY-NC-ND license.
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study was to evaluate the impact of a variety of clinicopatho-
logical factors as well as preoperative renal function on overall
survival (OS), cancer-speciﬁc survival (CSS), and bladder
recurrence-free survival (BRFS) in a cohort of patients following
RNU for primary UTUC.2. Materials and methods
2.1. Patients and data collection
We conducted this study by retrospective chart review. The
study protocol was approved by the Institutional Review Board of
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. A total
of 248 patients with UTUC undergoing RNU between January 2000
and June 2013 were enrolled. The exclusion criteria included
concomitant muscle-invasive bladder cancer, metastatic or bilat-
eral UTUC at initial presentation, perioperative chemotherapy or
radiotherapy, and incomplete clinical information. Clinical and
pathological data were recorded for each patient. Open or laparo-
scopic RNU was performed according to surgeons' preference.
Seventy-two patients (29.03%) received transurethral resection of
bladder tumor due to concomitant nonmuscle-invasive bladder
cancer (NMIBC).
Patients were followed-up postoperatively with urine cytology
and cystoscopy (every 3 months for the ﬁrst 2 years and every 6
months for the next 2 years, and every year thereafter). Chest X ray,
abdominal ultrasound, intravenous urography, and abdominal
computed tomographywere arranged every 3e6months according
to physician's consideration. The cause of death was conﬁrmed by
chart review and/or death certiﬁcate.2.2. Statistical analysis
Parameters including age, sex, cigarette smoking, estimated
renal function within 3 weeks prior to surgery, tumor location
(either pelvis or ureter, or simultaneously in both regions), patho-
logical tumor stage, lymph node metastasis, surgical modality,
bladder cuff management, and concomitant NMIBC were docu-
mented. As mentioned earlier, preoperative renal function was
estimated by eGFR, calculated using the Modiﬁcation of Diet in
Renal Disease study equation7:
186ðserum creatinineÞ1:154ðageÞ0:203ð0:742 if femaleÞ:
Patients with late-stage CKD (stage IV or V), characterized by
high hemodialysis rates, were qualitatively different from those
with early stage (stage I, II, or III) CKD in the disease complexity,
mortality, and economic impact.8 Therefore, patients were dichot-
omized into the early (eGFR  30 mL/min/1.73 m2) and late
(eGFR < 30 mL/min/1.73 m2) CKD groups. Tumors were staged
according to the American Joint Committee on Cancer tumor, node,
and metastasis classiﬁcation, 7th edition and graded using the 2004
World Health Organization/International Society of Urologic Pa-
thology consensus classiﬁcation. Bladder cuff was resected by the
transvesical, extravesical, or transurethral incision (TUI) method.
The detailed surgical technique was described previously.9
Survival rates were calculated from the date of RNU to the date
of all-cause mortality, cancer-speciﬁc death, bladder cancer recur-
rence, or last visit. All variables included were entered into multi-
variate Cox proportional hazard model to identify independent
predictors for OS, CSS, and BRFS. All statistical tests were performed
using SPSS version 19.0 (IBM Corp., Armonk, NY, USA) and statis-
tical signiﬁcance of p was set at 0.05.3. Results
Patients' demographic data are listed in Table 1. The median age
was 68 years (range, 24e95 years) with a slight female predomi-
nance (59.68%). Forty-seven cases (18.95%) were current smokers
and nearly one third of the patients (31.85%) had late-stage CKD.
Tumors were similarly located at the renal calyx/pelvis and ureter
(43.95% and 41.53%, respectively). As for pathological distribution,
47 patients (18.95%) were noninvasive (pTa/pTis), 73 patients
(29.44%) were pT1, 71 patients (28.63%) were pT2, 48 patients
(19.35%) were pT3, and nine patients (3.63%) were pT4. Seven cases
(2.82%) had lymph node metastasis and most were of high grade
(74.60%). Of the 248 patients, 152 (61.29%) underwent open RNU,
and 96 (38.71%) were treated by laparoscopic approach. As for
bladder cuff management, most patients received TUI or extra-
vesical methods (43.95% and 42.34%, respectively). In addition, all
clinicopathological parameters analyzed were not signiﬁcantly
different between the early and late-stage CKD groups except sex.
3.1. Survival analysis
The median follow-up was 45.4 months (range, 1e144 months).
Overall and cancer-speciﬁc death was recorded in 58 (23.39%) cases
and 32 (12.90%) cases, respectively, and 61 (24.60%) patients had
bladder cancer recurrence. The 5-year OS, CSS, and BRFS rates were
78.27%, 87.81%, and 70.42%, respectively.
In univariate analysis, aging, high-grade, nonorgan-conﬁned
primary tumor stage (pT3e4), lymph node involvement, and
bladder cuff management were signiﬁcantly associated with poor
OS (Table 2). Late-stage CKD had amarginal effect on OS (p¼ 0.073).
After multivariate adjustment, the independent predictors for OS
were aging [hazards ratio (HR), 1.78; 95% conﬁdence interval (CI),
1.04e3.04, p ¼ 0.037], late-stage CKD (HR, 1.96; 95% CI, 1.10e3.50,
p ¼ 0.023), and nonorgan-conﬁned primary tumor stage (HR, 2.00,
95% CI, 1.05e3.81, p ¼ 0.035).
As shown in Table 3, nonorgan-conﬁned primary tumor stage
and lymph node involvement were the only two signiﬁcant prog-
nostic factors associated with worse CSS in both univariate
(p < 0.001 in both cases) and multivariate (p ¼ 0.022 and p ¼ 0.017,
respectively) analyses.
Lastly, the presence of concomitant bladder tumor was a sig-
niﬁcant predictor for BRFS in univariate analysis (Table 4). In
multivariate Cox proportional hazard model, concomitant bladder
tumor posed an 11.76-fold increase in the risk of bladder cancer
recurrence (95% CI, 6.39e21.65; p < 0.001).
4. Discussion
UTUC is an uncommon cancer but its incidence in Taiwan is
much higher than across the world.2 RNU remains the gold-
standard treatment for UTUC although a number of nephron-
sparing surgeries are being developed. Several clinicopathological
factors have been reported to be associated with outcome of UTUC
patients following RNU, such as aging, multifocality, pathological
stage, lymphovascular invasion, surgical approach, and bladder cuff
management.10e15 Although the relationship between CKD and
UTUC has been discussed before,16e18 the inﬂuence of CKD on UTUC
outcome was seldom mentioned.
CKD is a rather common disorder in Taiwan with a prevalence
rate of 12% (95% CI, 11.66e12.28%).4 Patients having dialysis therapy
due to end-stage renal disease were at higher risk of various can-
cers, including UC.19e21 The underlying mechanism of cancer
development may possibly be related to impaired DNA repair,
immunocompromised status, nutritional deﬁciencies, and persis-
tent urinary tract irritation resulting from chronic infection/
Table 1
Clinicopathological characteristics of 248 patients treated for upper urinary urothelial carcinoma.
Patients (n ¼ 248) Early CKD (n ¼ 169) Late CKD (n ¼ 79) p
Age (y) 68 (24e95) 0.321
Sex
Male 100 (40.32) 76 (45) 24 (30.38) 0.041*
Female 148 (59.68) 93 (55) 55 (69.62)
Smoking 0.120
Yes 47 (18.95) 37 (21.89) 10 (12.66)
No 201 (81.05) 132 (78.11) 69 (87.34)
eGFR (mL/min/1.73 m2) 46.69 (2.90e154)
Early CKD (stage I, II, III) 169 (68.15)
Late CKD (stage IV, V) 79 (31.85)
Tumor location 0.168
Pelvis 109 (43.95) 79 (46.75) 30 (37.97)
Ureter 103 (41.53) 70 (41.42) 33 (41.77)
Both 36 (14.52) 20 (11.83) 16 (20.25)
Tumor grade 0.893
Low 63 (25.40) 42 (24.85) 127 (75.15)
High 185 (74.60) 21 (26.58) 58 (73.42)
Pathologic T stage 0.079
pT0epTaeTis 47 (18.95) 33 (19.53) 14 (17.72)
pT1 73 (29.44) 54 (31.95) 19 (24.05)
pT2 71 (28.63) 39 (23.08) 32 (40.51)
pT3 48 (19.35) 36 (21.30) 12 (15.19)
pT4 9 (3.63) 7 (4.14) 2 (2.53)
Pathologic N 0.548
Positive 7 (2.82) 6 (3.55) 1 (1.27)
Negative 241 (97.18) 163 (96.45) 78 (98.73)
Surgical modality 0.389
Open 152 (61.29) 100 (59.17) 52 (65.82)
Laparoscopy 96 (38.71) 69 (40.83) 27 (34.18)
Bladder cuff management 0.565
Transvesical approach 34 (13.71) 23 (13.61) 11 (13.92)
Extravesical approach 105 (42.34) 68 (40.24) 37 (46.84)
TUI 109 (43.95) 78 (46.15) 31 (39.24)
Concomitant bladder tumor 0.171
Yes 72 (29.03) 44 (26.04) 28 (35.44)
No 176 (70.97) 125 (73.96) 51 (64.56)
*p < 0.05.
Data are presented as n (%) or median (range).
CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration; TUI ¼ transurethral incision.
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discovered in the plants of the genus Aristolochia. Exposure to AA is
associated with renal function deterioration and UTUC develop-
ment owing to the formation of AAeDNA adducts and AA-induced
A:T to T:A transversions.25 Herbal medicines containing AA wereTable 2
Overall survival in univariate and multivariate analyses by Cox proportional hazard mod
Univariate a
HR (95% CI)
Age > 70 y vs. 70 y 1.76 (1.05e2.94)
Sex (female vs. male) 0.93 (0.55e1.59)
Smoking 0.77 (0.35e1.70)
Late-stage vs. early-stage CKD 1.63 (0.96e2.78)
Tumor location
Ureter vs. pelvis 1.37 (0.77e2.40)
Simultaneous vs. pelvis 1.42 (0.65e3.08)
Tumor grade (high vs. low) 2.04 (1.03e4.04)
Pathologic T > 2 vs. T  2 2.46 (1.44e4.22)
Pathologic N (pN1 vs. pN0 þ Nx) 4.39 (1.58e12.22)
Operation method (open vs. laparoscopy) 0.65 (0.37e1.13)
Bladder cuff management
Extravesical vs. transvesical 0.67 (0.34e1.29)
TUI vs. transvesical 0.38 (0.18e0.78)
Concomitant bladder tumor 1.11 (0.65e1.91)
*p < 0.05.
CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; HR ¼ hazards ratio; TUI ¼ tranused as remedies for weight loss, menstrual symptoms, and rheu-
matism in Asia, especially in Taiwan, Hong Kong, and China.26,27
Although the use of AA-containing herbal medicine was pro-
hibited in Asia since 2003,28 some AA-containing products are still
prescribed by Chinese medicine practitioners. Therefore, AA hasel.
Overall survival
nalysis Multivariate analysis
p HR (95% CI) p
0.033* 1.78 (1.04e3.04) 0.037*
0.807 0.93 (0.50e1.74) 0.826
0.520 0.74 (0.29e1.86) 0.521
0.073 1.96 (1.10e3.50) 0.023*
0.494 0.741
0.279 1.16 (0.63e2.13) 0.628
0.380 0.85 (0.37e1.97) 0.711
0.041* 1.84 (0.86e3.93) 0.114
0.001* 2.00 (1.05e3.81) 0.035*
0.005* 2.86 (0.86e9.45) 0.086
0.128 0.86 (0.45e1.62) 0.639
0.029* 0.057
0.228 0.52 (0.25e1.10) 0.087
0.009 0.39 (0.18e0.85) 0.018
0.703 1.31 (0.74e2.32) 0.354
surethral incision.
Table 3
Cancer-speciﬁc survival in univariate and multivariate analyses by Cox proportional hazard model.
Cancer-speciﬁc survival
Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age > 70 y vs.  70 y 1.60 (0.80e3.22) 0.183 1.70 (0.81e3.58) 0.161
Sex (female vs. male) 1.35 (0.67e2.70) 0.404 0.59 (0.26e1.32) 0.201
Smoking 0.79 (0.28e2.27) 0.668 0.43 (0.12e1.52) 0.193
Late-stage vs. early-stage CKD 1.04 (0.48e2.27) 0.914 1.39 (0.59e3.25) 0.448
Tumor location 0.933 0.698
Ureter vs. pelvis 1.01 (0.47e2.16) 0.977 0.79 (0.34e1.84) 0.587
Simultaneous vs. pelvis 1.21 (0.43e3.35) 0.720 0.62 (0.20e1.97) 0.421
Tumor grade (high vs. low) 2.28 (0.88e5.94) 0.091 1.84 (0.62e5.48) 0.276
Pathologic T > 2 vs. T  2 3.74 (1.86e7.50) <0.001* 2.75 (1.15e6.53) 0.022*
Pathologic N (pN1 vs. pN0 þ Nx) 8.70 (3.00e25.23) <0.001* 5.27 (1.35e20.61) 0.017*
Operation method (open vs. laparoscopy) 0.62 (0.29e1.33) 0.220 0.90 (0.38e2.13) 0.804
Bladder cuff management 0.236 0.324
Extravesical vs. transvesical 0.76 (0.29e1.96) 0.566 0.55 (0.19e1.54) 0.252
TUI vs. transvesical 0.43 (0.15e1.22) 0.114 0.44 (0.15e1.31) 0.141
Concomitant bladder tumor 1.10 (0.53e2.29) 0.801 1.51 (0.68e3.37) 0.312
*p < 0.05.
CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; HR ¼ hazards ratio; TUI ¼ transurethral incision.
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and UTUC in Taiwan.
Patients with CKD have been reported to be at risk of more
cardiovascular events and overall death irrespective of comorbid-
ities.29 In our analysis, late-stage CKD represented an independent
predictor for OS in UTUC patients. To our knowledge, this is the ﬁrst
study to demonstrate the predictive value of CKD on the outcome of
UTUC. However, CKD did not have a signiﬁcant effect on CSS and
BRFS in our multivariate analysis. It is hypothesized that the poor
survival caused by CKD is not directly through cancer progression.
Late-stage CKD is likely to be a surrogate for comorbidity status,
which leads to poor OS in UTUC.
Although CKD had always been described to be associated with
bladder cancer recurrence in Taiwanese UTUC patients, some lim-
itations existed. The case number was relatively small (150 pa-
tients) in the report by Chung et al,30 and our previous study used
serum creatinine alone to deﬁne CKD.31 More importantly, UTUC
patients receiving chemotherapy were not speciﬁcally excluded in
both previous studies. It has been demonstrated that adjuvant
chemotherapy may inﬂuence disease outcome, and patients withTable 4
Bladder recurrence-free survival in univariate and multivariate analyses by Cox proporti
Univariate an
HR (95% CI)
Age > 70 y vs. 70 y 1.38 (0.83e2.30)
Sex (female vs. male) 0.80 (0.48e1.33)
Smoking 0.86 (0.42e1.74)
Late-stage vs. early stage CKD 1.48 (0.88e2.49)
Tumor location
Ureter vs. pelvis 1.03 (0.60e1.77)
Simultaneous vs. pelvis 0.98 (0.44e2.14)
Tumor grade (high vs. low) 1.15 (0.66e1.99)
Pathologic T > 2 vs. T  2 0.52 (0.25e1.10)
Pathologic N (pN1 vs. pN0 þ Nx) 0.05 (0e94.60)
Operation method (open vs. laparoscopy) 0.88 (0.52e1.49)
Bladder cuff management
Extravesical vs. transvesical 0.85 (0.39e1.84)
TUI vs. transvesical 0.87 (0.41e1.84)
Concomitant bladder tumor 11.57 (6.39e20.92)
*p < 0.05.
CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; HR ¼ hazards ratio; TUI ¼ tranhigh-stage CKD preoperatively are barely eligible for cisplatin-
based chemotherapy after RNU. To clarify the actual effect of CKD
on UTUC outcome, we excluded cases receiving chemotherapy to
conduct our analysis. Our results showed that CKD did not inﬂu-
ence subsequent bladder cancer recurrence in our study. Thus, the
actual situation can be understood only upon excluding adjuvant
therapy.
The impact of concomitant NMIBC on survival is controver-
sial. Mullerad et al32 disclosed the relationship between NMIBC
and survival independent of primary tumor stage in a study of
129 patients in the United States; on the contrary, Youssef et al33
showed that a history of bladder carcinoma in situ, not NMIBC,
was associated with patient survival in a large multicenter study
in the United States. Milojevic et al34 in a single-center study of
221 Serbian patients also revealed that the history of NMIBC had
no effect on CSS, but was associated with bladder cancer
recurrence. Although concomitant bladder tumor had a great
impact on subsequent bladder cancer recurrence regardless of
primary tumor stage, the impact was limited to OS and CSS in
this study.onal hazard model.
Bladder recurrence-free survival
alysis Multivariate analysis
p HR (95% CI) p
0.211 1.75 (0.98e3.11) 0.057
0.394 0.60 (0.33e1.08) 0.085
0.664 0.82 (0.36e1.89) 0.644
0.137 1.49 (0.84e2.64) 0.175
0.990 0.874
0.919 1.07 (0.60e1.92) 0.821
0.949 0.86 (0.37e1.99) 0.732
0.621 0.95 (0.53e1.71) 0.859
0.087 0.78 (0.35e1.74) 0.540
0.433 0 0.977
0.639 0.77 (0.43e1.39) 0.392
0.916 0.862
0.685 0.87 (0.38e2.00) 0.749
0.710 0.80 (0.36e1.80) 0.595
<0.001* 11.76 (6.39e21.66) <0.001*
surethral incision.
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study of a single institute and selection bias cannot be completely
avoided. The result is interpreted cautiously and may not be
applicable globally. Second, all patients were enrolled in a single
medical center without external validation. Third, patients with a
history of bladder cancer were not excluded. Fourth, intake of
Chinese herbs medicine was not incorporated into analysis as the
detailed items and dosage of herbal consumption were lacking.
5. Conclusion
Patients with preoperative late-stage CKD had higher mortality
risk and were more likely to have shorter OS but not CSS.
Concomitant bladder tumor had a limited effect on both OS and CSS
although there was a great impact on BRFS. This information is
helpful in preoperative consultation and prompts a more delicate
and longer cystoscopy follow-up in patients with late-stage CKD
and concomitant bladder tumor in different situations.
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